Issuer Free Writing Prospectus

Filed Pursuant to Rule 433

Registration Statement No. 333-227122

Dated August 30, 2018

(To Preliminary Prospectus dated August 30, 2018)

Free Writing Prospectus

INmune Bio Inc. Company Presentation

This free writing prospectus relates to the proposed initial public offering of shares of common stock of INmune Bio Inc. (the “Company”), which are being registered on a Registration Statement on Form S-1 (No. 333-227122) (the “Registration Statement”). This free writing prospectus should be read together with the preliminary prospectus dated August 30, 2018 included in that Registration Statement, which can be accessed through the following link: http://www.sec.gov/Archives/edgar/data/1711754/000164033418001703/inmune_s1.htm

The Company has filed a registration statement (including a preliminary prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. The Registration Statement has not yet been declared effective by the SEC. Before you invest, you should read the preliminary prospectus in that registration statement (including the risk factors described therein) and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Univest Securities, LLC, Prospectus Department, at +1 (212)343-8888.